A new study indicates that the antiviral drug oseltamivir can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.
A new study indicates that the antiviral drug oseltamivir can reduce influenza infections and prevent deaths in a cost-saving manner under most pandemic scenarios.
Investigators’ analyses of phase II clinical data and information from a previous influenza outbreak revealed that oseltamivir 75 mg relative to no treatment was effective and affordable under all scenarios. Oseltamivir 150 mg relative to 75 mg was not cost effective in low transmissibility scenarios but was cost saving in high transmissibility scenarios.
“We used influenza as the critical exemplar for us to test the concept that interdisciplinary pharmacometrics can be applied where the pharmacokinetics/pharmacodynamics, clinical, or epidemiological endpoints of interest can eventually be linked to health economic value” said Prof. Carl Kirkpatrick co-author of the British Journal of Clinical Pharmacology study.
“This approach—which we have called ‘pharmacology to the payer’—can be applied across all disease areas and should facilitate greater dialogue between industry, regulators, payers, and patients earlier in the drug development process,” added co-author Craig Rayner.
Additional Information
Link to study: http://onlinelibrary.wiley.com/doi/10.1111/bcp.13229/abstract
About Journal
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology contains papers and reports on all aspects of drug action in humans: invited review articles, original papers and correspondence. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. Additionally supplements containing information on new methods, new drugs and new approaches to treatment are supplied free of charge.
Penny Smith-
+44 (0)1243 770171
sciencenewsroom@wiley.com